TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2
Brief Summary: The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. The study is also to examine the safety of MCI-186 to the ALS patients.


Options:
A: Arm Label: stem cell reciepient; Type: EXPERIMENTAL; Interventions: Biological: intrathecal injection | Intervention Type: BIOLOGICAL; Name: intrathecal injection; Assigned to Arm(s): stem cell reciepient
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: MCI-186, Drug: MCI-186 in open label phase | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: MCI-186 in open label phase | Intervention Type: DRUG; Name: MCI-186; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: MCI-186 in open label phase; Assigned to Arm(s): Arm 1, Arm 2
C: Arm Label: Transplant; Type: EXPERIMENTAL; Interventions: Procedure: Laminectomy and bone marrow stem cells transplantation, Procedure: Autologous bone marrow cells collection | Intervention Type: PROCEDURE; Name: Laminectomy and bone marrow stem cells transplantation; Assigned to Arm(s): Transplant | Intervention Type: PROCEDURE; Name: Autologous bone marrow cells collection; Assigned to Arm(s): Transplant
D: Arm Label: MSC-NTF; Type: EXPERIMENTAL; Interventions: Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | Intervention Type: BIOLOGICAL; Name: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF; Assigned to Arm(s): MSC-NTF

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Intra-arterial Reperfusion Therapy After Standard Dose Intravenous t-PA Within 4.5 Hours of Stroke Onset Utilizing Dual Target Imaging Selection.
Brief Summary: Patients presenting to the emergency department with acute ischaemic stroke, who are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be assessed for "dual target" major vessel occlusion and mismatch to determine their eligibility for randomisation into the trial. If the patient gives informed consent they will be randomised 50:50 using central computerised allocation to intra-arterial clot retrieval after IV tPA or IV tPA alone. The trial is prospective, randomised, open-label, blinded endpoint (PROBE) design.


Options:
A: N/A
B: Arm Label: Intra-arterial Clot Retrieval after iv tPA; Type: EXPERIMENTAL; Interventions: Device: Intra-arterial Clot Retrieval with Solitaire device | Arm Label: Standard care iv tPA; Type: ACTIVE_COMPARATOR; Interventions: Genetic: intravenous tissue plasminogen activator (tPA) | Intervention Type: DEVICE; Name: Intra-arterial Clot Retrieval with Solitaire device; Assigned to Arm(s): Intra-arterial Clot Retrieval after iv tPA | Intervention Type: GENETIC; Name: intravenous tissue plasminogen activator (tPA); Assigned to Arm(s): Standard care iv tPA
C: Arm Label: IV t-PA with Solitaire™ revascularization device; Type: EXPERIMENTAL; Interventions: Device: Solitaire revascularization device | Arm Label: IV t-PA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Intervention Type: DRUG; Name: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV t-PA | Intervention Type: DEVICE; Name: Solitaire revascularization device; Assigned to Arm(s): IV t-PA with Solitaire™ revascularization device
D: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Intra-arterial Reperfusion Therapy After Standard Dose Intravenous t-PA Within 4.5 Hours of Stroke Onset Utilizing Dual Target Imaging Selection.
Brief Summary: Patients presenting to the emergency department with acute ischaemic stroke, who are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be assessed for "dual target" major vessel occlusion and mismatch to determine their eligibility for randomisation into the trial. If the patient gives informed consent they will be randomised 50:50 using central computerised allocation to intra-arterial clot retrieval after IV tPA or IV tPA alone. The trial is prospective, randomised, open-label, blinded endpoint (PROBE) design.


Options:
A: Arm Label: endovascular thrombectomy therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Thrombectomy, Device: Trevo Retriever, Device: Solitaire™ FR Revascularization Device, Device: Penumbra thrombectomy system, Device: Covidien MindFrame Capture Revascularization Device | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endovascular Thrombectomy; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Trevo Retriever; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Solitaire™ FR Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Penumbra thrombectomy system; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Covidien MindFrame Capture Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy
B: Arm Label: 1 Mechanical Embolectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Merci Retriever and Penumbra System | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Merci Retriever and Penumbra System; Assigned to Arm(s): 1 Mechanical Embolectomy
C: Arm Label: Intra-arterial Clot Retrieval after iv tPA; Type: EXPERIMENTAL; Interventions: Device: Intra-arterial Clot Retrieval with Solitaire device | Arm Label: Standard care iv tPA; Type: ACTIVE_COMPARATOR; Interventions: Genetic: intravenous tissue plasminogen activator (tPA) | Intervention Type: DEVICE; Name: Intra-arterial Clot Retrieval with Solitaire device; Assigned to Arm(s): Intra-arterial Clot Retrieval after iv tPA | Intervention Type: GENETIC; Name: intravenous tissue plasminogen activator (tPA); Assigned to Arm(s): Standard care iv tPA
D: Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Solitaire FR device | Arm Label: Medical treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: DEVICE; Name: Solitaire FR device; Assigned to Arm(s): Endovascular treatment | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Intra-arterial Reperfusion Therapy After Standard Dose Intravenous t-PA Within 4.5 Hours of Stroke Onset Utilizing Dual Target Imaging Selection.
Brief Summary: Patients presenting to the emergency department with acute ischaemic stroke, who are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be assessed for "dual target" major vessel occlusion and mismatch to determine their eligibility for randomisation into the trial. If the patient gives informed consent they will be randomised 50:50 using central computerised allocation to intra-arterial clot retrieval after IV tPA or IV tPA alone. The trial is prospective, randomised, open-label, blinded endpoint (PROBE) design.


Options:
A: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA
B: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
C: Arm Label: IV t-PA with Solitaire™ revascularization device; Type: EXPERIMENTAL; Interventions: Device: Solitaire revascularization device | Arm Label: IV t-PA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Intervention Type: DRUG; Name: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV t-PA | Intervention Type: DEVICE; Name: Solitaire revascularization device; Assigned to Arm(s): IV t-PA with Solitaire™ revascularization device
D: Arm Label: Intra-arterial Clot Retrieval after iv tPA; Type: EXPERIMENTAL; Interventions: Device: Intra-arterial Clot Retrieval with Solitaire device | Arm Label: Standard care iv tPA; Type: ACTIVE_COMPARATOR; Interventions: Genetic: intravenous tissue plasminogen activator (tPA) | Intervention Type: DEVICE; Name: Intra-arterial Clot Retrieval with Solitaire device; Assigned to Arm(s): Intra-arterial Clot Retrieval after iv tPA | Intervention Type: GENETIC; Name: intravenous tissue plasminogen activator (tPA); Assigned to Arm(s): Standard care iv tPA

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center Study of the Effect of Sevelamer Carbonate (Renvela®) on Metabolic/Inflammatory/ROS in Diabetics With Nephropathy
Brief Summary: The purpose of this study is to see if taking a medication can lower the amount of oxidants from food that go into our body. Previous research shows that if the investigators lower the oxidants from food in people with diabetes, this simple change lowers different risks for heart disease and the worsening of kidney disease. The investigators focus on a specific type of oxidant, advanced glycation endproducts (AGEs). A previous, smaller study, conducted by our group showed that a drug, already approved by the FDA, will lower AGEs in the investigators compared Renvela® to Tums®. Both of these drugs have few side effects and have been used for a long time in patients with diabetes and kidney disease. While our previous study was interesting, it was just too small to be able to be sure that it will help all people with diabetes, or if the good effects the investigators found were simply due to chance. The investigators are doing this new study to confirm or deny the possibility that Renvela® can really help people with diabetes and kidney disease.


Options:
A: Arm Label: Ferric Citrate; Type: EXPERIMENTAL; Interventions: Drug: Ferric Citrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ferric Citrate; Assigned to Arm(s): Ferric Citrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sevelamer Carbonate; Type: EXPERIMENTAL; Interventions: Drug: Sevelamer Carbonate | Arm Label: calcium carbonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: calcium carbonate | Intervention Type: DRUG; Name: Sevelamer Carbonate; Assigned to Arm(s): Sevelamer Carbonate | Intervention Type: DRUG; Name: calcium carbonate; Assigned to Arm(s): calcium carbonate
C: Arm Label: Renal Function Group #1; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #2; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #3; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #4; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #5; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #6; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #7; Type: N/A; Interventions: N/A
D: Arm Label: Sevelamer; Type: EXPERIMENTAL; Interventions: Drug: Sevelamer | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sevelamer; Assigned to Arm(s): Sevelamer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Brief Summary: The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.


Options:
A: Arm Label: Bevacizumab combined with Fluzoparib; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: chemotherapy | Arm Label: Bevacizumab combined with chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: chemotherapy | Arm Label: Fluzoparib; Type: EXPERIMENTAL; Interventions: Drug: Fluzoparib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy | Intervention Type: DRUG; Name: chemotherapy; Assigned to Arm(s): Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy | Intervention Type: DRUG; Name: Fluzoparib; Assigned to Arm(s): Fluzoparib
B: Arm Label: Tivozanib; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Tivozanib; Assigned to Arm(s): Tivozanib
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo, Drug: Carboplatin | Arm Label: AMG 386; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386, Placebo | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): AMG 386, Placebo
D: Arm Label: Mirvetuximab Soravtansine; Type: EXPERIMENTAL; Interventions: Drug: Mirvetuximab Soravtansine | Arm Label: Investigator's Choice (IC) Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Topotecan, Drug: Pegylated liposomal doxorubicin | Intervention Type: DRUG; Name: Mirvetuximab Soravtansine; Assigned to Arm(s): Mirvetuximab Soravtansine | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Brief Summary: The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.


Options:
A: Arm Label: A - Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B - Paclitaxel + Bevacizumab followed by Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A - Paclitaxel, B - Paclitaxel + Bevacizumab followed by Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): B - Paclitaxel + Bevacizumab followed by Bevacizumab
B: Arm Label: Carboplatin and gemcitabine + bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Bevacizumab | Arm Label: Carboplatin and gemcitabine + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Carboplatin and gemcitabine + placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo, Drug: Carboplatin | Arm Label: AMG 386; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386, Placebo | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): AMG 386, Placebo
D: Arm Label: gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Arm Label: Gemcitabine + pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine, Drug: pazopanib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine + pazopanib, gemcitabine | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): Gemcitabine + pazopanib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol
Brief Summary: This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol.


Options:
A: Arm Label: Nurse intervention; Type: OTHER; Interventions: Other: Nurse intervention | Arm Label: Standard care; Type: OTHER; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Nurse intervention; Assigned to Arm(s): Nurse intervention | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
B: Arm Label: RDEA3170 2.5 mg, 7.5 mg and 15 mg; Type: EXPERIMENTAL; Interventions: Drug: RDEA3170 2.5 mg, Drug: allopurinol 300 mg | Arm Label: RDEA3170 5 mg, 10 mg and 20 mg; Type: EXPERIMENTAL; Interventions: Drug: RDEA3170 2.5 mg, Drug: allopurinol 300 mg | Intervention Type: DRUG; Name: RDEA3170 2.5 mg; Assigned to Arm(s): RDEA3170 2.5 mg, 7.5 mg and 15 mg, RDEA3170 5 mg, 10 mg and 20 mg | Intervention Type: DRUG; Name: allopurinol 300 mg; Assigned to Arm(s): RDEA3170 2.5 mg, 7.5 mg and 15 mg, RDEA3170 5 mg, 10 mg and 20 mg
C: Arm Label: lesinurad 200 mg + allopurinol; Type: EXPERIMENTAL; Interventions: Drug: Lesinurad, Drug: Allopurinol | Arm Label: lesinurad 400 mg + allopurinol; Type: EXPERIMENTAL; Interventions: Drug: Lesinurad, Drug: Allopurinol | Arm Label: Placebo + allopurinol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Allopurinol | Intervention Type: DRUG; Name: Lesinurad; Assigned to Arm(s): lesinurad 200 mg + allopurinol | Intervention Type: DRUG; Name: Lesinurad; Assigned to Arm(s): lesinurad 400 mg + allopurinol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + allopurinol | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Placebo + allopurinol, lesinurad 200 mg + allopurinol, lesinurad 400 mg + allopurinol
D: Arm Label: Febuxostat; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Working on Wellness (WOW): A Worksite Health Promotion Intervention Programme
Brief Summary: The main aim of this study is to measure the effectiveness of a worksite health promotion programme on improving physical activity behaviour and associated biological risk factors for cardiovascular disease among South African employees at increased risk for cardiovascular diseases. Additionally, the investigators will conduct an economic evaluation to determine the associated cost- effectiveness of these health related interventions offered at South African companies.

The investigators hypothesize that employees who receive the intervention counseling will have increased levels of physical activity and reduced risk for cardiovascular disease compared to those in the control group.


Options:
A: Arm Label: Novel workplace - first half; Type: EXPERIMENTAL; Interventions: Other: Workplace consisting of two height-adjustable desks | Arm Label: Novel workplace - second half; Type: EXPERIMENTAL; Interventions: Other: Workplace consisting of two height-adjustable desks | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Workplace consisting of two height-adjustable desks; Assigned to Arm(s): Novel workplace - first half, Novel workplace - second half
B: Arm Label: Tailored Physical Activity; Type: EXPERIMENTAL; Interventions: Other: Tailored Physical Activity | Arm Label: Reference group; Type: OTHER; Interventions: Behavioral: Health Counselling | Intervention Type: OTHER; Name: Tailored Physical Activity; Assigned to Arm(s): Tailored Physical Activity | Intervention Type: BEHAVIORAL; Name: Health Counselling; Assigned to Arm(s): Reference group
C: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Wellness counseling | Intervention Type: BEHAVIORAL; Name: Wellness counseling; Assigned to Arm(s): Lifestyle intervention
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention

Answer: C